Pfizer Advances Oral GLP-1 Development as the Race for Second-Gen Obesity Therapies Continues

Retrieved on: 2024-07-12 16:42:13

Tags for this article:

PEPTIDE THERAPEUTICS

Peptide hormones

Semaglutide

GLP-1 receptor agonist

Cagrilintide/semaglutide

Anti-obesity medication

Retatrutide

Tirzepatide

Glucagon-like peptide-1

Orforglipron

Eli Lilly and Company

Novo Nordisk

Glucagon-Like Peptide 1

Click the tags to see associated articles and topics

Pfizer Advances Oral GLP-1 Development as the Race for Second-Gen Obesity Therapies Continues. View article details on hiswai:

Summary

The article discusses Pfizer's development of danuglipron, an oral GLP-1 receptor agonist, aligning with the key concept 'Biotech'. The tags like 'Semaglutide', 'Tirzepatide', and 'GLP-1 receptor agonist' connect to the broader context of advanced peptide-based anti-obesity medications.

Article found on: www.drugtopics.com

View Original Article